Literature DB >> 30821843

Cobicistat as a Pharmacoenhancer in Pregnancy and Postpartum: Progress to Date and Next Steps.

Ahizechukwu C Eke1,2, Mark H Mirochnick3.   

Abstract

Entities:  

Keywords:  cobicistat; pharmacoenhancers; postpartum; pregnancy; ritonavirzzm321990

Mesh：

Substances：

Year:  2019        PMID： 30821843      PMCID： PMC9228990          DOI： 10.1002/jcph.1397

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN： 0091-2700            Impact factor:   2.860


× No keyword cloud information.
  15 in total

1.  Enrolling pregnant women in research--lessons from the H1N1 influenza pandemic.

Authors:  Sara F Goldkind; Leyla Sahin; Beverly Gallauresi
Journal:  N Engl J Med       Date:  2010-06-17       Impact factor: 91.245

2.  A pregnancy physiologically based pharmacokinetic (p-PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4.

Authors:  Lu Gaohua; Khaled Abduljalil; Masoud Jamei; Trevor N Johnson; Amin Rostami-Hodjegan
Journal:  Br J Clin Pharmacol       Date:  2012-11       Impact factor: 4.335

3.  Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection.

Authors:  Richard Elion; Calvin Cohen; Joseph Gathe; Peter Shalit; Trevor Hawkins; Hui C Liu; Anita A Mathias; Steven L Chuck; Brian P Kearney; David R Warren
Journal:  AIDS       Date:  2011-09-24       Impact factor: 4.177

4.  Increasing the Participation of Pregnant Women in Clinical Trials.

Authors:  Katrina Heyrana; Heather M Byers; Pamela Stratton
Journal:  JAMA       Date:  2018-11-27       Impact factor: 56.272

Review 5.  Cobicistat Versus Ritonavir: Similar Pharmacokinetic Enhancers But Some Important Differences.

Authors:  Alice Tseng; Christine A Hughes; Janet Wu; Jason Seet; Elizabeth J Phillips
Journal:  Ann Pharmacother       Date:  2017-06-19       Impact factor: 3.154

Review 6.  Physiologically-based pharmacokinetic (PBPK) models for assessing the kinetics of xenobiotics during pregnancy: achievements and shortcomings.

Authors:  G Lu; K Abduljalil; M Jamei; T N Johnson; H Soltani; A Rostami-Hodjegan
Journal:  Curr Drug Metab       Date:  2012-07       Impact factor: 3.731

7.  Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results.

Authors:  Joel E Gallant; Ellen Koenig; Jaime Andrade-Villanueva; Ploenchan Chetchotisakd; Edwin DeJesus; Francisco Antunes; Keikawus Arastéh; Graeme Moyle; Giuliano Rizzardini; Jan Fehr; Yapei Liu; Lijie Zhong; Christian Callebaut; Javier Szwarcberg; Martin S Rhee; Andrew K Cheng
Journal:  J Infect Dis       Date:  2013-03-26       Impact factor: 5.226

8.  Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.

Authors:  E M Connor; R S Sperling; R Gelber; P Kiselev; G Scott; M J O'Sullivan; R VanDyke; M Bey; W Shearer; R L Jacobson
Journal:  N Engl J Med       Date:  1994-11-03       Impact factor: 91.245

9.  Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial.

Authors:  Joseph J Eron; Jean-Daniel Lelievre; Robert Kalayjian; Jihad Slim; Anson K Wurapa; Jeffrey L Stephens; Cheryl McDonald; Eric Cua; Aimee Wilkin; Brigitte Schmied; Mehri McKellar; Stephanie Cox; Sophia R Majeed; Shuping Jiang; Andrew Cheng; Moupali Das; Devi SenGupta
Journal:  Lancet HIV       Date:  2018-12-13       Impact factor: 12.767

10.  Phase IIIb, open-label single-arm trial of darunavir/cobicistat (DRV/COBI): Week 48 subgroup analysis of HIV-1-infected treatment-nave adults.

Authors:  Karen Tashima; Gordon Crofoot; Frank L Tomaka; Thomas N Kakuda; Anne Brochot; Simon Vanveggel; Magda Opsomer; William Garner; Nicolas Margot; Joseph M Custodio; Marshall W Fordyce; Javier Szwarcberg
Journal:  J Int AIDS Soc       Date:  2014-11-02       Impact factor: 5.396
View more
  8 in total

Review 1.  Pharmacokinetic Enhancement of HIV Antiretroviral Therapy During Pregnancy.

Authors:  Engie Salama; Ahizechukwu C Eke; Brookie M Best; Mark Mirochnick; Jeremiah D Momper
Journal:  J Clin Pharmacol       Date:  2020-08-14       Impact factor: 3.126

Review 2.  Prediction and prevention of preterm birth in pregnant women living with HIV on antiretroviral therapy.

Authors:  Amanda J Jones; Uzoamaka A Eke; Ahizechukwu C Eke
Journal:  Expert Rev Anti Infect Ther       Date:  2022-03-01       Impact factor: 5.854

Review 3.  An update on the physiologic changes during pregnancy and their impact on drug pharmacokinetics and pharmacogenomics.

Authors:  Ahizechukwu C Eke
Journal:  J Basic Clin Physiol Pharmacol       Date:  2021-12-08

4.  Fosamprenavir with Ritonavir Pharmacokinetics during Pregnancy.

Authors:  Ahizechukwu C Eke; Jiajia Wang; Khadija Amin; David E Shapiro; Alice Stek; Elizabeth Smith; Nahida Chakhtoura; Michael Basar; Kathleen George; Katherine M Knapp; Esaú C João; Kittipong Rungruengthanakit; Edmund Capparelli; Sandra Burchett; Mark Mirochnick; Brookie M Best
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

5.  Darunavir Pharmacokinetics With an Increased Dose During Pregnancy.

Authors:  Ahizechukwu C Eke; Alice M Stek; Jiajia Wang; Regis Kreitchmann; David E Shapiro; Elizabeth Smith; Nahida Chakhtoura; Edmund V Capparelli; Mark Mirochnick; Brookie M Best
Journal:  J Acquir Immune Defic Syndr       Date:  2020-04-01       Impact factor: 3.771

Review 6.  Tenofovir alafenamide use in pregnant and lactating women living with HIV.

Authors:  Ahizechukwu C Eke; Kristina M Brooks; Rahel D Gebreyohannes; Jeanne S Sheffield; Kelly E Dooley; Mark Mirochnick
Journal:  Expert Opin Drug Metab Toxicol       Date:  2020-03-17       Impact factor: 4.936

7.  Optimizing Pharmacology Studies in Pregnant and Lactating Women Using Lessons From HIV: A Consensus Statement.

Authors:  Ahizechukwu C Eke; Adeniyi Olagunju; Jeremiah Momper; Martina Penazzato; Elaine J Abrams; Brookie M Best; Edmund V Capparelli; Adrie Bekker; Yodit Belew; Jennifer J Kiser; Kimberly Struble; Graham Taylor; Catriona Waitt; Mark Mirochnick; Tim R Cressey; Angela Colbers
Journal:  Clin Pharmacol Ther       Date:  2020-10-15       Impact factor: 6.875

8.  Innovative Approaches for Pharmacology Studies in Pregnant and Lactating Women: A Viewpoint and Lessons from HIV.

Authors:  Ahizechukwu C Eke; Adeniyi Olagunju; Brookie M Best; Mark Mirochnick; Jeremiah D Momper; Elaine Abrams; Martina Penazzato; Tim R Cressey; Angela Colbers
Journal:  Clin Pharmacokinet       Date:  2020-10       Impact factor: 6.447
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.